Selective estrogen receptor downregulators (SERDs)

Fulvestrant

TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced breast cancer (metastatic)

fulvestrant
EFECT (Chia)fulvestrant 250mgexemestaneNegativeNCT00065325
9238IL/0025fulvestrant 250mgtamoxifen - NCT00241449
9238UK/0005 (combination)fulvestrant + anastrozoleexemestane - NCT00944918
9238UK/0005 (fluvestrant alone)fluvestrant 250mgexemestane - NCT00944918
0021 (Osborne), 2002fulvestrant 250mganastrozoleNegativeNCT00635713
0020 (Howell), 2002fulvestrant 250mganastrozoleNegative
0025 (Howell), 2004fulvestrant 250mgtamoxifenNegative
CONFIRM (Di Leo), 2010fulvestrant 500mgfulvestrant 250mg - NCT00099437
FINDER 1 (Ohno), 2010fulvestrant 500mgfulvestrant 250mg -
FINDER 2, 2010fulvestrant 500mgfulvestrant 250mg Exploratory - NCT00313170
FIRST (Robertson), 2010fulvestrant 500mganastrozoleSuggestingNCT00274469
Xu et al., 2011fulvestrant 250mganastrozole - NCT00327769
SoFEa (Johnston) combination, 2012fulvestrant + anastrozoleexemestaneNegativeNCT00253422
FACT (Bergh), 2012fulvestrant + anastrozoleanastrozoleNegativeNCT00256698
Mehta(SWOG-S0226), 2012fulvestrant + anastrozoleanastrozoleSuggestingNCT00075764
SoFEa (Johnston) fluvestrant alone, 2012fluvestrant 250mgexemestane - NCT00253422
D6997L00021fulvestrant 500mgfulvestrant 250mg - NCT01300351
GEICAM/2006-10fulvestrant + anastrozoleanastrozole - NCT00543127
A011106 ongoing fulvestrant 250mganastrozole - NCT01953588
CDR0000349337 ongoing fulvestrant + anastrozoleanastrozole - NCT00075764
FALCON ongoing fulvestrant 500mganastrozole - NCT01602380
FUMANCE ongoing fulvestrant 500mgcontrol - NCT02383030